Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial

Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    2%
    Check dated 2025-06-20T06:41:48.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.8%
    Check dated 2025-06-13T01:02:26.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T21:05:08.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation.
    Difference
    3%
    Check dated 2025-05-29T16:02:40.000Z thumbnail image
  5. Check
    53 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T03:59:59.000Z thumbnail image
  6. Check
    67 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding a Phase II trial for Chronic Lymphocytic Leukemia (CLL) and the addition of collaborators and a new revision number.
    Difference
    18%
    Check dated 2025-04-16T14:31:02.000Z thumbnail image

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.